Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00177047 · ClinicalTrials.gov registry record · Phase 2
Autologous Transplant for Multiple Myeloma
A Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 363
- Enrollment target
NCT00177047 is a Phase 2 study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 363 participants.
The verdict
NCT00177047, a Phase 2 study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 363 participants
- Enrollment target
Study Summary
This is a study of a regimen of melphalan and autologous stem cells for patients with multiple myeloma. We hypothesize that this particular regimen will improve the survival of these patients.
Interventions
- DRUG Melphalan
- PROCEDURE Stem Cell Transplant
- DRUG Cyclophosphamide + Mesna
- BIOLOGICAL Granulocyte-colony stimulating factor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 363 participants |
| Start Date | 2004-04-20 |
| Est. Completion | 2020-08-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00177047
The ClinicalTrials.gov registry entry for NCT00177047 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 363 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Melphalan is the first listed.
NCT00177047 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00177047 about?
NCT00177047 is a clinical study titled "Autologous Transplant for Multiple Myeloma". This is a study of a regimen of melphalan and autologous stem cells for patients with multiple myeloma. We hypothesize that this particular regimen will improve the survival of these patients.
What is the current status of trial NCT00177047?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 363 participants. The study started on 2004-04-20. Estimated completion is 2020-08-01.
What interventions are being tested in trial NCT00177047?
The interventions under investigation include: Melphalan (DRUG), Stem Cell Transplant (PROCEDURE), Cyclophosphamide + Mesna (DRUG), Granulocyte-colony stimulating factor (BIOLOGICAL).
Who is sponsoring clinical trial NCT00177047?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.